Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Decreases By 18.3%

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 21,500 shares, a drop of 18.3% from the November 30th total of 26,300 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 26,200 shares, the short-interest ratio is currently 0.8 days.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new position in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises approximately 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned 15.76% of KALA BIO as of its most recent filing with the Securities and Exchange Commission. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a research report on Friday, November 15th.

KALA BIO Price Performance

Shares of KALA BIO stock traded up $0.05 on Friday, hitting $6.98. 26,650 shares of the company traded hands, compared to its average volume of 77,790. KALA BIO has a 52 week low of $4.21 and a 52 week high of $9.25. The business has a 50-day simple moving average of $6.56 and a 200 day simple moving average of $6.23. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. The stock has a market capitalization of $32.18 million, a P/E ratio of -0.56 and a beta of -2.15.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. Research analysts expect that KALA BIO will post -10.84 earnings per share for the current fiscal year.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.